This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caron, F.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caron, F.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Dec 1997, 2749-2753, Vol 41, No. 12
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium

F Caron, HS Gold, CB Wennersten, MG Farris, RC Moellering Jr and GM Eliopoulos
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

RP 59500, a mixture of two semisynthetic streptogramin antibiotics (quinupristin and dalfopristin), is one of a few investigational agents currently in clinical trials with inhibitory activity against multiple- drug-resistant strains of Enterococcus faecium. We evaluated the bactericidal activity of this antimicrobial against 30 recent clinical isolates of vancomycin-resistant E. faecium, including 23 erythromycin- resistant (MIC, >256 microg/ml) and 7 erythromycin-intermediate (MIC, 2 to 4 microg/ml) strains. All isolates were inhibited by RP 59500 at 0.25 to 1.0 microg/ml. The bactericidal activity of RP 59500 was markedly influenced by the erythromycin susceptibility of the strains and by several technical factors, such as inoculum growth phase and time of incubation of counting plates. As determined by time-kill methods, RP 59500 at a concentration of 2 or 8 microg/ml failed to kill erythromycin-resistant organisms under any conditions. Bactericidal activity was observed against all seven erythromycin-intermediate isolates when log-phase inocula were used and the cells were counted after 48 h of incubation (mean reductions in viable bacteria for RP 59500 at concentrations of 2 and 8 microg/ml, 3.45 and 3.50 log10 CFU/ml, respectively), but killing was diminished when the plates were examined at 72 h (mean killing, 3.06 and 2.95 log10, CFU/ml, respectively). No bactericidal activity was observed when stationary- phase cultures were used. On the basis of these data, we expect that bactericidal activity of RP 59500 against the multiple-drug-resistant E. faecium strains currently encountered would be distinctly uncommon.


This article has been cited by other articles:

  • Pfaller, M. A., Sheehan, D. J., Rex, J. H. (2004). Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization. Clin. Microbiol. Rev. 17: 268-280 [Abstract] [Full Text]  
  • Eliopoulos, G. M., Wennersten, C. B. (2002). Antimicrobial Activity of Quinupristin-Dalfopristin Combined with Other Antibiotics against Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 46: 1319-1324 [Abstract] [Full Text]  
  • Jones, R. N., Hare, R. S., Sabatelli, F. J., Ziracin Susceptibility Testing Group, T. (2001). In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. J Antimicrob Chemother 47: 15-25 [Abstract] [Full Text]  
  • Zeckel, M. L., Preston, D. A., Allen, B. S. (2000). In Vitro Activities of LY333328 and Comparative Agents against Nosocomial Gram-Positive Pathogens Collected in a 1997 Global Surveillance Study. Antimicrob. Agents Chemother. 44: 1370-1374 [Abstract] [Full Text]  
  • Murray, B. E. (2000). Vancomycin-Resistant Enterococcal Infections. NEJM 342: 710-721 [Full Text]  
  • Moellering, R. C., Linden, P. K., Reinhardt, J., Blumberg, E. A., Bompart, F., Talbot, G.H. (1999). The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 44: 251-261 [Abstract] [Full Text]  
  • Schlegel, L., Sissia, G., Fremaux, A., Geslin, P. (1999). Diminished Killing of Pneumococci by Pristinamycin Demonstrated by Time-Kill Studies. Antimicrob. Agents Chemother. 43: 2099-2100 [Full Text]  
  • Schmitz, F.-J., Verhoef, J., Fluit, A. C., The Sentry Participants Group, (1999). Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. J Antimicrob Chemother 43: 783-792 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Zervos, M. J., Rybak, M. J. (1998). Treatment of Vancomycin-Resistant Enterococcus faecium with RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 42: 2710-2717 [Abstract] [Full Text]  
  • Aeschlimann, J. R., Rybak, M. J. (1998). Pharmacodynamic Analysis of the Activity of Quinupristin-Dalfopristin against Vancomycin-Resistant Enterococcus faecium with Differing MBCs via Time-Kill-Curve and Postantibiotic Effect Methods. Antimicrob. Agents Chemother. 42: 2188-2192 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»